Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 5/20 | 0.50 |
| ▸ | BCL6 | P41182 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026856 | 0.81 | CDK1 (0.41) | KDM4E | |
| SCHEMBL5026867 | 0.81 | CDK1 (0.41) | KDM4E | |
| SCHEMBL5024375 | 0.79 | NCF1 (0.67) | NCF1MAPTADRB2ADRB1GAA | |
| SCHEMBL5025361 | 0.79 | NCF1 (0.53) | NCF1MAPTSMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL27597817 | 0.76 | NCF1 (0.52) | NCF1MAPTSMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL5035764 | 0.75 | NCF1 (0.48) | NCF1MAPTSMN1; SMN2ADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL5033328 | 0.74 | NCF1 (0.47) | NCF1MAPTSMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL5026895 | 0.73 | NCF1 (0.51) | NCF1MAPTADRB2ADRB1GAA | |
| SCHEMBL27700780 | 0.73 | KDM4E (0.46) | MAPTSMN1; SMN2GAAKDM4EKMT2A | |
| SCHEMBL5024412 | 0.73 | NCF1 (0.53) | NCF1MAPTSMN1; SMN2ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474145-B1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-23 | — | — | EP | disclosed |
| CN-1627945-A | Quinoline derivatives as NPY antagonists | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | CN | disclosed |
| EP-1474145-A1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-6696467-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-24 | — | — | US | disclosed |
| WO-2003066055-A1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
| US-20030153553-A1 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153553-A1 | Quinoline derivatives | NPY1R, NPY4R, GLP1R | NCF1 1858/4885BCL6 4398/4885MAPT 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.